 WHIPPANY, N.J. SOUTH SAN FRANCISCO, Calif.--BUSINESS WIRE--Bayer and Atara Biotherapeutics, Inc. Nasdaq: ATRA today announced an exclusive worldwide license agreement and research, development and manufacturing collaboration for mesothelin-directed CAR T-cell therapies for the treatment of solid tumors. The agreement includes the development candidate ATA3271, an armored allogeneic T-cell immunotherapy, and an autologous version, ATA2271, for high mesothelin-expressing tumors such as mali 